These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30392324)

  • 1. [Establishment and evaluation of a triple-color human papillomavirus pseudovirion neutralization assay].
    Wei SP; Fan F; Chen J; Liu XL; Yang YR; Wang ZP; Song S; Li ZH; Wei MX; Wang DN; Li SW; Xia NS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Oct; 52(10):1039-1044. PubMed ID: 30392324
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
    Nie J; Liu Y; Huang W; Wang Y
    Viruses; 2016 Apr; 8(4):107. PubMed ID: 27120611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a triple-color pseudovirion-based neutralization assay for immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.
    Gao S; Zhao D; Feng C; Kou Y; Lu J; Luo C; Li X; Wang Y; Xie L
    J Med Virol; 2024 Aug; 96(8):e29859. PubMed ID: 39145587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
    Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
    Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
    Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
    Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.
    Kemp TJ; Matsui K; Shelton G; Safaeian M; Pinto LA
    Hum Vaccin Immunother; 2015; 11(2):337-46. PubMed ID: 25695397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
    Pastrana DV; Buck CB; Pang YY; Thompson CD; Castle PE; FitzGerald PC; Krüger Kjaer S; Lowy DR; Schiller JT
    Virology; 2004 Apr; 321(2):205-16. PubMed ID: 15051381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
    Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
    Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.
    Sehr P; Rubio I; Seitz H; Putzker K; Ribeiro-Müller L; Pawlita M; Müller M
    PLoS One; 2013; 8(10):e75677. PubMed ID: 24124504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity correlation in cynomolgus monkeys between Luminex-based total IgG immunoassay and pseudovirion-based neutralization assay for a 14-valent recombinant human papillomavirus vaccine.
    Bei L; Zhang X; Meng D; Gao S; Jia J; Zhao D; Luo C; Li X; Qiu H; Xie L
    J Med Virol; 2022 Aug; 94(8):3946-3955. PubMed ID: 35388509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
    Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT
    Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies.
    Hu X; Chen Y; Lin W; Ruan Q; Chen H; Li X; Deng Y; Liang C; Lin H; Zeng L; Sun N; Zhao W; Chen L; Yang Y; Sun L; He J; Sun J
    J Med Virol; 2024 Sep; 96(9):e29910. PubMed ID: 39228341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
    Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
    Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells.
    Lamprecht RL; Kennedy P; Huddy SM; Bethke S; Hendrikse M; Hitzeroth II; Rybicki EP
    Sci Rep; 2016 Feb; 6():20431. PubMed ID: 26853456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
    Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The preliminary analysis on immunogenicity of DNA vaccines against human papillomavirus 58].
    Wu XL; Nie JH; Zhang CT; Wu Y; Zhao CY; Wang YC
    Bing Du Xue Bao; 2008 May; 24(3):196-201. PubMed ID: 18683556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.